October 23, 2012 — In the DEBATE-SFA trial, researchers found that the use of a paclitaxel drug-eluting balloon (DEB) to widen the artery prior to implanting a self-expanding nitinol stent yielded a lower restenosis rate after one year. Results of the trial were presented at the 24^th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

At RSNA 2012, GE Healthcare will be showcasing a comprehensive portfolio of ultrasound products for use across a broad range of patient exam types. Among the products to be highlighted will be the newly enhanced Logiq E9, Logiq S8 and others in the LOGIQ family.

QuantiaMD, the largest online physician community, and The International CardiOncology Society (ICOS) announced at the ICOS 6th annual meeting in Milan, Italy a partnership to launch the ICOS global physicians collaboration forum on QuantiaMD. This first-of-its-kind partnership brings together an emerging area of medicine with QuantiaMD’s dynamic clinical exchange to rapidly drive awareness, education and training around the cardiac implications of oncology treatments.

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced six-month clinical, IVUS (Intravascular Ultrasound), OCT (Optical Coherence Tomography) and angiographic data for its 15-patient First-In-Man clinical study of the fully bioresorbable drug-eluting scaffold, the DESolve Bioresorbable Coronary Scaffold System at a late-breaking trial session of EuroPCR in Paris.